Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study-Reference-Cited by-同舟云学术

Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study

Published:2024-04-28 Issue:1 Volume:13 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Jia Siyue¹,Yin Zundong²,Pan Hongxing¹,Wang Fuzhen²,Liu Xiaoqiang³,Wang Qing⁴,Zhang Li⁵,Tang Jihai⁶,Yang Hao⁷,Du Jiangbo⁸,Wang Zhiguo¹,Jin Pengfei¹,Peng Zhihang⁸,Tang Rong¹,Kang Guodong¹,Wang Xuewen⁹,Li Simin¹⁰,Wang Weixiao⁸,Li Jingxin¹⁸¹⁰,Shen Hongbing⁸²,Zhu Fengcai¹⁸¹⁰

Affiliation:

1. NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of China

2. China Center for Disease Control and Prevention, Beijing, People’s Republic of China

3. Yunnan Provincial Center for Disease Control and Prevention, Kunming, People’s Republic of China

4. Chongqing Provincial Center for Disease Control and Prevention, Chongqing, People’s Republic of China

5. Shandong Provincial Center for Disease Control and Prevention, Jinan, People’s Republic of China

6. Anhui Provincial Center for Disease Control and Prevention, Hefei, People’s Republic of China

7. Hunan Provincial Center for Disease Control and Prevention, Changsha, People’s Republic of China

8. National Vaccine Innovation Platform and Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China

9. Canming Medical Technology Co., Ltd, Shanghai, People’s Republic of China

10. School of Public Health, Southeast University; Nanjing, People’s Republic of China

Funder

National Natural Science Foundation of China

Major Research Plan of the National Natural Science Foundation of China

Science Fund for Distinguished Young Scholars of Jiangsu Province

Jiangsu Provincial Key Project of Science and Technology Plan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2024.2332660

Reference29 articles.

1. World Health Organization. Interim recommendations for heterologous COVID-19 vaccination schedules [cited 2023 11 April]. Available from: https://www.who.int/news/item/16-12-2021-interim-recommendations-for-heterologous-covid-19-vaccine-schedules.

2. Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China

3. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

5. Trends of SARS-CoV-2 Infection in Rural Area in Sentinel Community-Based Surveillance — China, December 2022 to January 2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV;Emerging Microbes & Infections;2024-08-30